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Abstract
Background: Individuals with advanced HIV infection naïve
to antiretroviral therapy represent a special population of
patients frequently encountered in clinical practice. They are
at high risk of disease progression and death, and their viro-
immunologic response following the initiation of highly
active antiretroviral therapy may be more incomplete or slower
than that of other patients. Infection management in such
patients can also be complicated by underlying conditions,
comorbidities, and the need for concomitant medications.
Aim: To provide practical guidelines to those clinicians
providing care to HIV-infected patients in terms of diagnostic
assessment, monitoring, and treatment.
Conclusions: The principals of antiretroviral treatment in
asymptomatic naïve patients with advanced HIV infection
are the same as those applicable to the general population
with asymptomatic HIV infection. Naïve patients with
advanced HIV infection and a history of AIDS-defining
illnesses urgently need antiretroviral treatment, with the
choice of antiretroviral regimen and timetable based on such
factors as concomitant treatment and prophylaxis, drug
interactions, and potential concomitant drug toxicity.
Finally, an adequate counseling program – both before and
after HIV-testing – that includes aspects other than treat-
ment adherence monitoring is a crucial step in disease
management.
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Introduction
Despite a general awareness of the fact that early HIV
screening is advisable, a considerable proportion of indi-
viduals in developed countries receive a new diagnosis of
HIV infection at an advanced disease stage, when AIDS-
related diseases or symptoms are already present [1–3].
High plasma HIV-RNA levels and low CD4+ cell counts,
typically found in advanced stages of HIV disease, are
both associated with an increased risk of mortality, even
after the initiation of combination antiretroviral therapy
(cART) [4, 5]. In addition, even after cART has been
initiated, early viro-immunologic response may be
incomplete or slower in patients with more advanced HIV
infection at baseline [6, 7], and it is also strongly associ-
ated with subsequent disease progression [8].
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Proper clinical management of antiretroviral ther-
apy in patients with advanced HIV infection by appro-
priate, timely, and efficacious prescriptions is therefore
crucial to an improved prognosis [9, 10]. When treating
special patient populations, clinicians also need to take
into account co-morbidities, concomitant treatments,
and medical problems specific to that particular patient
population.
This document is a consensus statement resulting
from a consensus conference of experts and clinicians
active in the field of HIV infection and treatment. This
aim of this conference was to outline our current under-
standing of advanced HIV infection clinical management
and develop recommendations for clinicians.
Methods
The recommendations presented here are the result of a con-
sensus workshop which took place in Rome, Italy, on December
2006. The 2-day workshop started with two introductory plenary
lectures held by international experts on the issues covered by
the consensus conference. Thereafter, a draft of the statements
and a grading system classifying the strength of the recommen-
dations and the quality of evidence were presented by 27 Italian
experts in the field, who had previously searched, reviewed, and
synthesized the literature specifically pertaining to the topics.
The strength of the recommendations was graded as strong (A),
moderate (B), and optional (C); the quality of the evidence was
classified as I, indicating properly randomized controlled trials
with clinical and/or laboratory results; II, indicating other pub-
lished studies with clinical and/or laboratory results; III, indi-
cating expert opinion. Four main topics were covered:
1. diagnostic assessments and monitoring of naı¨ve patients with
advanced HIV infection;
2. principles of antiretroviral treatment in naı¨ve patients with
asymptomatic advanced HIV infection;
3. principles of antiretroviral treatment and monitoring of
naı¨ve patients with advanced HIV infection and opportu-
nistic disorders, and at high risk of death (AIDS presenter);
4. principles of antiretroviral treatment and monitoring of
naı¨ve patients with advanced HIV infection and special
conditions or co-morbidities.
Four working groups, each comprising 10–15 Italian HIV-
treating physicians, reviewed and modified these preliminary
statements according to the current literature and their personal
clinical experiences. The revised statements were presented in a
plenary session and voted by all consensus participants: they
were then either accepted or re-discussed and re-voted according
to the degree of agreement reached.
Diagnostic Assessments and Monitoring in Naïve
Patients with Advanced HIV Infection
Introduction
The early and correct identification of patients with an
advanced naı¨ve HIV infection is addressed here. A cor-
rect definition of the laboratory tests recommended for
these patients at baseline and follow-up visits is essential
to disease staging, monitoring of eventual therapy-related
toxicities, and risk assessment of opportunistic infections.
Initial clinical management is crucial for these patients,
since it will represent the basis for a trusting relationship
with the health care staff.
Definition of Advanced Naïve HIV-Infection
Patients with advanced HIV infection naı¨ve to antiretro-
virals are individuals presenting with one or both of the
following two conditions at HIV diagnosis: (1) stage C
according to 1993 Revised Classification System for HIV
infection [11] (A-II); (b) CD4+ T cell count £ 200/mm3
on two consecutive determinations (B-II). However, this
definition should be viewed in a larger context. Older age
(‡ 60 years) or coexisting illnesses at diagnosis of HIV
infection could also be included in the definition of ad-
vanced naı¨ve patients, if the negative effects of these
conditions on quality of life, disease progression, immu-
nologic response to treatment, and cART-related toxici-
ties are taken into account [12] (B-II).
As a result of the clinical complexity of naı¨ve patients
with advanced HIV infection [2], clinicians should make
every possible effort to facilitate early detection of HIV
infection (A-II).
Patient Support
Special care and psychological support of patients with
advanced naı¨ve HIV infection during the initial clinical
assessment are necessary. Patients may have to receive
many different pieces of information at the same time:
positive test for HIV antibody, urgency of promptly
starting cART and, perhaps, the need for treatment of
opportunistic infections. Therefore, adequate counseling
both before and after HIV-testing is crucial (A-II).
Depending on the patients’ desire to conceal or disclose
their HIV status to trusted family members, partners, and
friends, the latter may become involved in the patient
support counseling.
HIV-Surrogate Markers and Resistance Testing
On a routine basis, blood examinations, such as complete
blood cell count and chemistry profile (A-III), lympho-
cyte cell count (absolute and percentage value of both
CD4+ and CD8+ T cells) (A-I) [13], and plasma HIV-
RNA levels (viral load) [4] (A-I), need to be assessed at
the first and all follow-up visits (Table 1). Two distinct
baseline measurements of CD4+ T cell count should be
obtained – at least 1 week apart if possible – because of a
possible variation in results (C-III). Although the absolute
CD4+ T cell count is the most commonly used parameter
in clinical practice, the percentage of CD4+ T cells is
somewhat less variable than the absolute count, and the
latter may provide additional information when immune
function is assessed (C-III). Other lymphocytic subpopu-
lations, such as CD8/CD38+ T cells, are measurable and
may be considered a marker of both disease progression
and response to treatment regardless of other viro-
immunologic parameters (C-III). During opportunistic
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infections (e.g., tuberculosis, cytomegalovirus [CMV]),
virologic and immunologic parameters may be less helpful
than usual in evaluating the risk of disease progression in
single patients since they may be wrongly reduced or
elevated [14]. Viro-immunologic parameters should be
repeated in these cases (A-II).
Genotypic resistance testing should be carried out
[15] (A-II) and viral subtype determination performed
(B-III) in all naı¨ve patients with advanced HIV infection.
Regardless of the imminent necessity to start cART, the
genotypic assay is helpful in guiding the selection of
treatment strategies [15]. Nevertheless, there is no reason
for delaying the initiation of cART while awaiting the
results of the test in patients at a high risk of disease
progression: in these cases, treatment should be started
promptly using drugs with a high genetic barrier and
eventually modified thereafter on the basis of the result of
the genotypic test (A-III). In terms of research applied to
genotypic resistance testing, it could be interesting to
consider innovative methodologies to identify specific
mutations as minority quasi-species (e.g., single genome
assay or allele-specific PCR for detecting the K103N
mutation) [16] (B-III).
In the future, the determination of HIV-1 cell
receptor (CCR5, CXCR4, or mixed/dual CXCR4/CCR5)
tropism may be appropriate to design innovative strate-
gies by using entry inhibitors in early phases of treatment.
Nevertheless, this test currently does not seem to provide
additional information since no significant differences in
mean CD4+ T cell count increases in patients with either
CXCR4- or CCR5-tropic HIV-1 have been observed [17].
Although an investigation of other virologic markers, such
as proviral DNA, appears to be interesting in terms of
gaining a better understanding of the pathogenetic
mechanism of HIV and being able to better evaluate the
response to cART, it should not yet be considered a part
of standard monitoring procedures (B-III).
Other Laboratory Assessments
The hypersensitivity reaction to abacavir is strongly
associated with the presence of the HLA-B*5701
allele and, therefore, pharmacogenetic testing should
be used to prevent the specific toxic effect of the drug [10,
18] (A-I).
Adequate screening of the hepatitis viruses (HV)
determining chronic disease (HCV, HBV, HDV) needs to
be carried out (Table 1) (A-III). False negative results of
some diagnostic tests may occur in patients with advanced
HIV infection, particularly in patients with strong immu-
nosuppression; such results generally concern antibodies
against hepatitis B surface antigen, HCV, and Toxo-
plasma gondii [19]. Based on this fact, despite HCV-
antibody negativity, determination of plasma HCV-RNA
should be performed in all patients with advanced HIV
infection having unexplained high levels of serum trans-
aminases (B-II).
The tuberculin skin test is yet another test whose re-
sult may be affected by the loss of cellular immune
function. A chest radiograph should be performed in the
presence of respiratory symptoms – even if no skin indu-
ration ‡ 5 mm is evident – and three sputum samples
should be collected to investigate the presence of acid-fast
bacilli as well as to culture for mycobacteria (A-II). A low
sensitivity to the skin tuberculin test will be overcome, in
part, by the introduction of two blood tests (T-SPOT.TB
and Quantiferon-TB Gold), which are based on the
detection of IFN-gamma released by T lymphocytes in
response to Mycobacterium tuberculosis-specific antigens.
Clinical studies examining these new tests in the HIV
patient population are in progress [20].
Additional Tests
A baseline chest radiograph should be reserved for all
patients with advanced HIV infection and naı¨ve to anti-
retroviral therapy, particularly if they have a prior history
of pulmonary disease or active pulmonary problems
(A-III). An electrocardiogram should be considered as a
Table 1
Laboratory examinations that should be performed in patients
with advanced naïve HIV infection at baseline and/or on a
routine basis.
Hematology Complete blood count
Lymphocyte subpopulations
Serum chemistry Fasting blood glucose
Electrolytes (Na/K/Ca/P), creatinine
Transaminase levels, bilirubin, cGT, LDH, CK
Albumin
Alkaline phosphatase, amylase
Fasting triglycerides, cholesterol
(total, HDL, LDL)
Urinalysis
C-reactive protein
Virological tests Plasma HIV RNA
Viral subtype
Genotypic resistance test
Serological tests RPR or VDRL (confirmatory test FTA-ABS)
CMV Ag and IgG/M, EBV IgG/M
Toxoplasma gondii IgG
Cryptococcal antigen
HBsAg, HBsAb, HBcAb, HCV IgG, HAV IgG
Cytology Papanicolaou smear test of the cervix
Microbiology Search for pathogens responsible of other
sexually transmitted diseases
(such as Chlamydia trachomatis, Neisseria
gonorrhoeae, HPV-PCR and genotyping)
cGT: c-Glutamyl transferase; LDH: lactate dehydrogenase; CK: cre-
atine kinase; HDL: high-density lipoprotein; LDL: low-density
lipoprotein; RPR: rapid plasma reagin; VDRL: venereal disease re-
search laboratory; FTA-ABS: fluorescent treponemal antibody
absorption; CMV: cytomegalovirus; EBV: Epstein-Barr virus; HBsAg:
surface antigen of the Hepatitis B virus; HbsAb: hepatitis B surface
antibody; HBcAb: hepatitis B core antibody; HCV: hepatitis C virus;
HAV: hepatitis A virus; HPV: human papillomavirus
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component of the initial assessment if clinically indicated
(B-III). Finally, routine screening for health-maintenance
issues, particularly those defined by age-appropriate
standard-of-care, should be included (e.g., prostate-spe-
cific antigen determination, mammography, test for occult
blood in stool) (B-III).
Opportunistic Diseases and Concomitant
Conditions
Patients with advanced naı¨ve HIV infection carry a sub-
stantially increased risk of the following concomitant condi-
tions that may complicate clinical management by worsening
disease prognosis and response to treatment [3, 12]:
• presence of opportunistic infections [1];
• co-morbidities, such as chronic liver diseases, malig-
nancies, etc. [12];
• older age [13, 21];
• immune reconstitution inflammatory syndrome (IRIS)
[22, 23];
• need for concomitant medications (e.g., concomitant
prevention/treatment of opportunistic infections);
• psychological distress.
In particular, the presence of concomitant opportunistic
diseases should be evaluated by assessing the following
(A-II):
– medical history and complete physical examination;
– routine blood tests (hematology and chemistry);
– instrumental examinations based on specific signs and
symptoms (chest X-ray, brain CT scan, endoscopy, etc.);
– biopsy samples (e.g., lymph node, liver);
– serological and virological tests as well as cultures
(where appropriate) to detect specific opportunistic
pathogens (CMV, Pneumocystis jiroveci, mycobacte-
ria, T. gondii, Cryptococcus neoformans, etc.).
A funduscopic examination in patients having a CD4+ T
cell count < 100/mmc may be appropriate (B-II).
Advanced naı¨ve patients should receive an intensive
follow-up program, especially during the initial treatment
phase (B-II) because the risk of opportunistic infections
during the first 12 months is reduced, but not eliminated
by cART [24–27].
Monitoring Antiretroviral Therapy Efficacy and
cART-Related Toxicities
One month after initiating cART, treatment efficacy
should be evaluated by determining lymphocyte subpop-
ulations (absolute and percentage value of CD4+ T cells)
(A-I), and plasma HIV-RNA levels (A-I). Once an anti-
retroviral treatment has begun, patients should be care-
fully monitored by means of blood tests in order to guard
against the risk of different cART-related toxicities
(A-II). It may also be advisable to store a blood sample
for future diagnostic procedures (C-III).
Advanced naı¨ve HIV patients are generally older
than early HIV presenters: both advanced age and HIV
infection are associated with an increase in cardiovascular
risks. Moreover, prolonged exposure to cART, in partic-
ular to regimens containing protease inhibitors, induces
metabolic alterations that represent an additional risk
factor for cardiovascular events. Hence, the assessment,
monitoring, and correction of likely cardiovascular risk
factors should be implemented [28] (A-II).
Immune Reconstitution Inflammatory Syndrome
Immune reconstitution inflammatory syndrome is a clini-
cal condition observed in some AIDS patients, in which
the immune system begins to recover and to respond to a
previously acquired opportunistic infection with an over-
whelming inflammatory response that paradoxically
worsens the symptoms of infection. Since the onset of IRIS
highly complicates the management of naı¨ve patients with
advanced HIV infection, strategies to prevent IRIS by
identifying patients with possible ongoing opportunistic
infections during the initial phase of cART treatment
should be developed [22, 23] (B-II). As IRIS has been
associated with the reactivation of the organism’s response
to almost all opportunistic infections, a well-established
diagnostic procedure should be elaborated (B-II).
Principles of Antiretroviral Treatment in Naïve
Patients with Asymptomatic Advanced HIV
Infection
Introduction
The principal objectives of cART are to reduce HIV-related
morbidity and mortality, to restore immune system, to sup-
press viral replication as long as possible, and to improve
quality of life. The decision of when to initiate antiretroviral
treatment in asymptomatic patients should be based on their
prognosis, as determined by the CD4+ T cell count and
plasma HIV-RNA values at the baseline visit, possible drug-
related toxicity, and adherence issues [4, 8, 21].
In general, the principles of antiretroviral treatment
in this sub-group of patients are the same as those appli-
cable to the general population with asymptomatic HIV
infection. Therefore, only special concepts of advanced
naı¨ve patients with respect to the general HIV population
will be highlighted in the present guidelines.
General Recommendations
Based on the results of randomized trials and observa-
tional cohorts which focused on the high risk of disease
progression, the initiation of antiretroviral treatment is
strongly recommended in all patients with a CD4+ T cell
count < 200/mm3 [4, 8, 21, 29] (A-I). In these patients
antiretroviral treatment should be started as soon as
possible (A-II) and be coupled with both a previous
comprehensive clinical as well as pharmacological evalu-
ation and an accurate counseling program on adherence
to treatment [30] (A-III).
A. Antinori et al. Italian Consensus Statement
Infection 37 Æ 2009 Æ No. 3  URBAN & VOGEL 273
Taking into consideration both the risk of clinical
progression and the relevance of achieving a prompt
suppression of viral replication, the panel strongly rec-
ommends that initial antiretroviral regimen be selected on
the basis of HIV genotypic test results [15] (A-II).
Choice of Antiretroviral Treatment
Randomized prospective trials comparing treatment
strategies in exclusively advanced patients are few and
therefore desirable. Preliminary data on the short-medium
efficacy and safety of first-line antiretroviral regimens are
derived from observational studies as well as randomized
trials, including asymptomatic patients without CD4+ T
cells count restriction.
A virologic, but not immunologic, superiority has
been documented for non-nucleoside reverse transcrip-
tase inhibitors (NNRTI)-based regimens when these are
compared to mostly unboosted protease inhibitor (PI)-
based cART in randomized trials and retrospective cohort
studies [31, 32]. One randomized comparative trial per-
formed in a naı¨ve patient population containing a relevant
proportion (about 40%) of patients with advanced HIV
infection showed that lopinavir/ritonavir (LPV/r)-con-
taining regimens were associated with a better CD4+ T
cell count increase as well as with a reduced risk of
resistance mutation development at treatment failure,
while efavirenz-containing regimens showed more likely
virologic success [33]. Data from prospective observational
studies did not show substantial differences between
NNRTI-based and PI/r-based regimens with reference
to virologic efficacy and/or clinical outcome [34, 35].
However, in prospective non-randomized studies and in
non-comparative randomized trials, LPV/r-containing
regimens had a persistent immunologic efficacy, a better
immunologic recovery, and no primary resistance-associ-
ated mutation development in patients with suppressed
viral load [36, 37].
Based on the finding that regimens including other
boosted-PIs showed non-inferior results, as evidenced in
comparative trials at short-term follow-up, these can be
considered for regimen building [38–40] (B-I).
While numerous data are available on the potency of
regimens containing efavirenz [32, 34], empirical evidence
for using regimens containing nevirapine in this population
is limited (B-I). Even if specific studies on a direct com-
parison are lacking, regimens containing non-thymidine
nucleoside analogues seem to be more desirable since they
are associated with a better CD4+ cells recovery (B-I).
Antiretroviral regimens containing four drugs, based
either on a combination of drugs belonging to all three
antiretroviral drug classes (NRTI–NNRTI–PI) or on the
association of three nucleoside analogues and an NNRTI
drug, did not show an advantage relative to the standard
of care [41]. Based on available data, antiretroviral
treatment with PI/r monotherapy is not advisable in this
patient population [42] (A-I). To date, data are inade-
quate for supporting the introduction of fusion inhibitors
[43] or immunomodulators (e.g. IL-2) in the first antiret-
roviral regimens (A-II).
Concomitant Treatments
The risk of opportunistic infections in patients with
advanced naı¨ve HIV infection persists throughout the
entire phase of immunosuppression and even lasts several
months following the start of cART [25, 26]. For this
reason, patients with low CD4+ T cell counts should
receive primary prophylaxis for opportunistic infections
(A-II). The drug regimens used for specific opportunistic
infections and the CD4+ T cell count below which pro-
phylaxis is indicated are summarized in table 2.
Table 2
Type of regimen for primary prophylaxis of opportunistic infections and timing.
PCP Toxoplasmic encephalitis MAC infection
CD4+ T cell count below which
prophylaxis should be started
< 200 cells/mm3 < 100 cells/mm3 < 50 cells/mm3
Preferred regimen Trimethoprim-sulfamethoxazole
double-strength (DS) tablet
1 tablet by mouth daily (A-I)
1 tablet by mouth three times
weekly (B-II)
Trimethoprim-sulfamethoxazole
DS 1 tablet by mouth daily (A-I)
Clarithromycin 500 mg by mouth
twice daily (A-I)
Azithromycin 1,200 mg by mouth
weekly (A-I)
Alternative regimen Aerosolized pentamidine 300 mg
monthly via aerosol
Dapsone 100 mg by mouth daily
Atovaquone 1,500 mg by mouth
daily
Dapsone 50 mg by mouth daily
plus pyrimethamine 50 mg by
mouth weekly plus leucovorin
25 mg by mouth weekly
Atovaquone 1,500 mg by mouth
daily
Rifabutin 300 mg by mouth daily
CD4+ T cell count above which
prophylaxis should be
discontinued
> 200 cells/mm3 for ‡ 3 months > 100 cells/mm3 for ‡ 3 months
MAC: Mycobacterium avium complex; PCP: P. jiroveci pneumonia
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Since there are no documented interactions between
drugs used for primary prophylaxis of either P. jiroveci
pneumonia (PCP) or toxoplasmic encephalitis (trimetho-
prim/sulphamethoxazole, dapsone, pentamidine) and
currently available antiretrovirals, these can be used
without concern (A-III).
PIs and NNRTIs are metabolized in the liver by the
cytochrome P450 system, particularly by CYP3A4, so that
drug–drug interaction should be checked in the presence of
concomitant medications (A-III). Since rifamycins in gen-
eral (rifabutin to a lesser extent) are CYP3A4 inducers, they
should be used with caution when administered in associ-
ation with other drugs inducing or inhibiting the same
cytochrome enzyme (A-III). In fact, they can significantly
reduce plasma concentrations of most PIs and NNRTIs.
Since interactions between macrolides and antiretro-
viral drugs do not seem to be clinically significant, dosage
modifications are not necessary (A-III).
Adherence
Adherence to antiretroviral treatment is crucial to obtain
and maintain virological suppression, to avoid the occur-
rence of HIV resistance, and to prolong survival [44–46].
Patient-reported non-adherence is a valid tool for assess-
ing suboptimal antiretroviral intake and correlates with
major treatment outcomes [44, 45, 47]. Clinicians should
be able to reassure the patient while emphasizing the
importance of adherence and the risks associated with an
incorrect intake of the prescribed treatments (A-II).
Interaction between patients and their health care
providers should be close and constant in order that the latter
be able to carefully evaluate treatment adherence and to
promptly monitor the onset of side effects possibly related to
cART or, eventually, to other concomitant treatments.
Adequate counseling to reinforce adherence (A-I), provide
psychological support, and treat potential psychiatric disor-
ders and drug dependence (A-II) should be considered both
before and during the administration of cART.
Principles of Antiretroviral Treatment and
Monitoring in Naïve Patients with Advanced HIV
Infection, Opportunistic Disorders and High Risk
of Death (Aids Presenter)
Introduction
Advanced naı¨ve HIV-positive patients presenting with
AIDS-defining illnesses or severe symptoms are at an
extremely high risk of developing other opportunistic
conditions or dying [3, 23] and, therefore, urgently need
antiretroviral treatment. This topic focuses on issues
concerning the timing of cART initiation and the type of
treatment regimen to be used.
Timing of cART During Opportunistic Infections
and Malignancies
Antiretroviral treatment must be started in all HIV-in-
fected patients with a diagnosis of AIDS and should be
initiated, in the absence of contraindications, during the
early stages of acute opportunistic infections [10, 48] (A-I).
cART per se should be considered a therapeutic strategy
for all opportunistic disorders for which an etiologic treat-
ment against a specific agent is lacking: cryptosporidiosis,
microsporidiosis, progressive multifocal leukoencephalopa-
thy (PML), and localized cutaneous and mucosal Kaposi’s
sarcoma [3] (A-III). In these cases, cART should be started
immediately, without awaiting the results of an HIV geno-
typic resistance test, preferably using high-genetic barrier
drugs (A-III).
In the case of opportunistic infection for which an
etiologic treatment is available (M. avium-complex
infection [MAC], PCP, cryptococcal meningitis, CMV
infection, toxoplasmic encephalitis, esophageal candidia-
sis), cART may be deferred until stabilization of the
clinical condition of the patient [3]. It is advisable, how-
ever, not to postpone the initiation of cART beyond
14 days from disease diagnosis, considering that immedi-
ate cART is associated with reduced death and AIDS
progression and a shorter time to immune recovery
[48–50] (C-I).
The following factors should be considered in the
decision-making process on when to start cART:
• degree of immunosuppression;
• toxicity related to concomitant treatments;
• risk of IRIS;
• type of pathogen.
cART has been shown to improve outcome in ventilator-
supported patients hospitalized in the intensive care unit
with severe PCP and to be an independent predictor of
decreased mortality [51]. Thus, in patients with PCP,
cART needs to be started before completion of the acute
phase of anti-P. jiroveci treatment to avoid any possible
complication of the clinical picture [52] (B-III). It is
important that if there is either evidence of clinical
worsening or a lack of response to etiologic treatment,
cART should be started during the first 14 days (C-III).
Patients who receive the combination of cancer che-
motherapy and cART may achieve better response rates
than patients who receive antineoplastic therapy alone
[53]. Some studies have reported that patients with
Hodgkin’s lymphoma (HL) or non-Hodgkin’s lymphoma
(NHL) who started cART at the same time as chemo-
therapy showed increased survival [54–56], reduced
toxicity (especially bone marrow toxicity), and a decreased
risk of developing opportunistic infections. Therefore,
cART should be started before or at the same time as
chemotherapy in patients diagnosed with HL, NHL, or
Kaposis’s sarcoma (A-I).
In patients with a diagnosis of non-AIDS-defining
malignancies, antiretroviral treatment should be consid-
ered before or at the same time as chemotherapy treat-
ment (C-III). While the benefit of cART in patients with
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HL is supported by clinical evidence [57], there is no
evidence of such an advantage in other malignancies.
However, the unreliability of close immunologic moni-
toring, the clinical advantages observed in patients with
HL and NHL, and the strong scientific rationale regarding
anti-tumoral immunity support the starting of cART in
this group of patients as well.
Choice of Antiretroviral Drugs
In terms of treatment efficacy, there is at yet no clear
evidence of which is the best initial regimen (e.g. PI/r- or
NNRTI-based cART) to be used to treat patients with
ongoing HIV-related malignancies and opportunistic
infections (C-III). Combinations of cART and treatments
against opportunistic infections should be carefully
selected in order not to overlap bone marrow, renal, or
hepatic toxicities (A-II). In particular, NNRTIs should
be avoided when therapy-induced hepatic toxicity is
expected, zidovudine should not be used in case of pos-
sible mielotoxicity, tenofovir should not be considered in
the presence of renal impairment, and didanosine/stavu-
dine/zidovudine should not be included in the case of
possible peripheral neurological toxicity (B-III).
It is likely that PIs should be preferred as part of an
initial cART in the presence of a number of opportunistic
infections, such as Candida spp, P. jiroveci, and Crypto-
coccus spp, since these drugs have shown a direct in vitro
activity on these pathogens (C-III).
Optimal initial antiretroviral treatment options have
not yet been established in patients with Kaposi’s sarcoma.
Both PI/r- and NNRTI-containing regimens have been
shown to have comparable antiviral activity in reducing
Kaposi’s sarcoma-associated herpesvirus (KSHV) viremia.
Nevertheless, based on in vitro experimental data, clinical
evidence, and single case reports, several experts suggest the
initial use of PI/r-containing regimens (C-III).
The start of antiretroviral therapy during tuberculosis
treatment in naı¨ve patients with advanced HIV infection
may be safe and effective [58]. Tuberculosis treatment
should preferably include rifampicin (A-II) and, due
to drug–drug interactions, cART should be based on
efavirenz together with two NRTI drugs (A-II). When a
PI-containing regimen is adopted, rifampicin should be
replaced by rifabutin (A-I). When rifabutin is prescribed
in association with PI/r or NNRTI, the dosage of the
former drug should be modified (A-III). The regimens of
tuberculosis therapy and timing of cART are summarized
in table 3 based on the degree of immune-suppression at
the diagnosis of tuberculosis.
Immune Reconstitution Inflammatory Syndrome
For all patients with tuberculosis, MAC, CMV retinitis,
cryptococcal meningitis, and PML, the starting antiretro-
viral treatment should be accurately evaluated for the
onset of IRIS [22, 23] (A-II). Studies have shown that the
risk of IRIS is associated with baseline CD4 cell count as
well as early initiation of cART and that severe, life-
threatening manifestations are uncommon [48, 59, 60].
IRIS should be treated with anti-inflammatory drugs,
such as nonsteroidal anti-inflammatory drugs (NSAIDs)
or steroids, to control symptoms, and antiretroviral
treatment should be continued. It may be necessary to
stop antiretroviral treatment if the clinical picture of IRIS
is severe (C-III).
Prophylaxis Against Opportunistic Infections
In all patients with symptomatic advanced naı¨ve HIV
infection, primary prophylaxis against opportunistic infec-
tions other than those already diagnosed should be initiated
as soon as possible (A-I). Drugs for primary prophylaxis can
be prescribed at the same time as cART and other treat-
ments for concomitant opportunistic infections (Table 2).
Secondary prophylaxis for opportunistic infections
may be stopped once a stable immune recovery is reached
by cART [61–66] (A-I). CD4+ T cell levels at which
secondary prophylaxis can be withdrawn are shown in
table 4.
Principles of Antiretroviral Treatment and
Monitoring in Naïve Patients with Advanced HIV
Infection and Special Conditions or Co-morbidities
Introduction
This section examines the issues pertinent to naı¨ve patients
with advanced HIV infection and special conditions or co-
morbidities. Attention will focus on special populations,
such as the elderly, who show a slower immune recovery,
Table 3
Type of antitubercular therapy and timing of cART based on immuno-suppression at diagnosis of tuberculosis.
CD4+ T cell count Antitubercular treatmenta cART Recommendationb
< 100 cells/mm3 Rifampicin-based Add after the first 15 days C-III
100, 200 cells/mm3 Rifampicin-based Add at completion of the initial phase of antitubercular
therapy or at least after the first month
C-III
200–350 cells/mm3 Rifampicin-based Evaluate cART indication every 2 months C-III
> 350 cells/mm3 Rifampicin-based Evaluate cART indication after 2 months and
thereafter every 3 months
C-III
cART: Combination antiretroviral therapy; a If a protease-inhibitor-containing regimen is adopted, rifampicin should be replaced by rifabutin;
b The strength of the recommendations was graded: C, optional; the quality of the evidence was classified: III, expert opinion
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patients with neurocognitive disorders, who are frequently
observed during severe immunosuppression [67, 68], and
those co-infected with hepatitis viruses [69, 70].
Older Age
After starting cART, older patients show a reduced
recovery of CD4+ T cells and an increased risk of pro-
gression to AIDS diagnosis, neurocognitive disorders, and
death with respect to younger patients having comparable
levels of CD4+ T cells and HIV viral loads [67, 68].
Therefore, in this patient population, the initiation of
cART could be indicated at an earlier stage of disease. At
the present time, cART must to be started at least when
the CD4+ T cell level < 350/mmc (A-III) and may be
considered in patients with CD4+ T cells between 350 and
500/mm3 and plasma HIV-1 RNA levels > 30,000 cp/ml
(A-III). Specific studies on this topic are warranted.
Neurocognitive Impairment
In advanced naı¨ve HIV patients or in patients with
neurocognitive impairment not taking antiretroviral
treatment, HIV-1 viral load level in the CSF correlates
with the severity of HIV-related dementia and, therefore,
may predict subsequent onset of neurocognitive impair-
ments [68, 69]. In all patients presenting with neurological
signs and symptoms in whom a diagnostic lumbar punc-
ture is indicated, the measurement of HIV-RNA in CSF
should be added to all specific tests being performed to
diagnose opportunistic infections (A-II).
All patients with advanced naı¨ve HIV infection
should undergo an accurate assessment of neuropsycho-
logical status using a validated cognitive test battery or a
standardized scale for clinical measurements [71, 72]. This
assessment should be repeated during follow-up in pa-
tients having a cognitive impairment and an abnormal
baseline test result (A-II).
Patients with neurocognitive disorders and/or detect-
able HIV-1 RNA levels in the CSF before cART has been
started should be prescribed antiretroviral regimens con-
taining neuroactive drugs with a high penetration score in
CSF [68, 73, 74] (A-II). In the case of worsening clinical
conditions and/or of neurocognitive tests, these patients
should undergo lumbar puncture both to assess HIV-1
RNA levels in the CSF and to perform genotypic resis-
tance test on the CSF virus in order to choose the most
appropriate therapeutic option (B-III).
Co-Infection with Hepatic Viruses
Liver disease is one of the major causes of morbidity and
mortality in HIV-infected patients [75, 76], and its severity
has been associated with more advanced immunosuppres-
sion. HCV/HIV co-infection may accelerate HIV-related
neurocognitive decline [69]. Further, HCV viremia seems
to play a role in impairing the CD4+ T cell count response
to cART [70]. On the other hand, effective antiretroviral
drugs use may contribute to worsening the liver disease
[77]. Reversal or prevention of immunosuppression with
cART will slow the progression of HCV disease.
The analyses to be performed in advanced naı¨ve pa-
tients having abnormal liver function tests are summa-
rized in table 5.
In advanced naı¨ve patients with chronic HCV infec-
tion, therapy with peg-IFN plus ribavirin is indicated:
– in all subjects achieving an adequate immune recon-
stitution and a stabilization of antiretroviral therapy,
in the absence of contraindications, and following
specific guidelines (A-II);
– when hepatopathy related to HCV co-infection repre-
sents a major obstacle to proper antiretroviral treat-
ment (C-III).
All HBsAg-positive patients having HBV DNA levels
> 2,000 IU/ml and/or cirrhosis should receive an antiret-
roviral regimen containing tenofovir (TDF) (possibly
associated with 3TC/FTC) as part of the NRTI backbone
(A-III). In patients in which TDF use is contraindicated or
must be stopped, adefovir or entecavir should be used
(B-II). It should be noted that entecavir is a potent partial
inhibitor of HIV replication in vivo and in vitro and that it
may select for viruses bearing the M184V mutation [78].
Therefore in HBV/HIV-coinfected patients, entecavir
should not be used for the treatment of HBV infection
without concomitant suppressive treatment for HIV
(B-II). In subjects diagnosed with HBV-related cirrhosis,
especially if the continuous performance test (CPT) score
is > 5, a pre-emptive treatment with entecavir or adefovir
before starting cART may be considered in order to re-
duce the risk of decompensation during the phase of im-
mune reconstitution (C-III). Before starting or modifying
treatment against chronic HBV infection, it may be useful
to have a HBV genotype test performed in order to
identify mutational patterns that confer resistance to
drugs against HBV (B-III).
Patients who are HBsAg- and/or HBcAb-positive and
undergoing a period of severe immunodepression fol-
Table 4
CD4+ T cell levels at which secondary prophylaxis may be with-
drawn.
Opportunistic
infection
CD4+ T cell count Recommen-
dationa
P. jiroveci pneumonia > 200 cells/mm3 ‡ 3 months A-I
Cytomegalovirus
infection
> 100 cells/mm3 ‡ 6 months A-II
Toxoplasmic
encephalitis
> 200 cells/mm3 ‡ 6 months A-I
Cryptococcosis > 100 cells/mm3 ‡ 6 months B–I
MAC infection > 100 cells/mm3 ‡ 6 months B-II
a The strength of the recommendations was graded: A, strong; B,
moderate; the quality of the evidence was classified: I, properly
randomized controlled trials with clinical and/or laboratory results;
II, other published studies with clinical and/or laboratory results
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lowing chemotherapy for neoplasms should receive pro-
phylaxis against hepatitis B reactivation (A-I) with cART
containing TDF associated with or without 3TC/FTC, or
alternatively entecavir (A-III).
No antiretroviral drug is contraindicated at the early
stages of hepatopathy. In patients with advanced hepa-
topathy, antiretroviral regimens containing either TPV/
RTV (A-II), nevirapine (A-II), d-drugs (A-II), or abaca-
vir (C-III) should be avoided [79].
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